Famotidine for the improvement of cognitive impairments in COVID-19 patients

Phase 2

• Conditions: COVID-19.; COVID-19, virus identified; U07.1

• Registration Number: IRCT20090117001556N138
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 30 August 2021

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

History of hospitalization due to COVID-19
At least 20 days from the onset of symptoms, and 7 days from the last day of symptoms passed
Diagnosis of cognitive impairment (score 23 or less in MMSE test, or score 22 or less in MoCA test)
Age between 18-65

Exclusion Criteria

Being psychotic
Presence of other psychiatric disorders
Using other psychiatric drugs or any drug which can affect cognitive performance
History of ECT during past 2 months
Presence of thyroid disease
Presence of kidney disease
Presence of liver disease
History of cognitive impairment or dementia
Pregnant or lactating women

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of cognitive impairment. Timepoint: Baseline and months 1.5 and 3. Method of measurement: by Mini mental state Exam (MMSE), Montreal Cognitive Assessment (MoCA), Hamilton Depression Rating Scale (HAM-D), Hamilton Anxiety Rating Scale (HAM-A).